BCX-1812 (RWJ-270201): Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design-Reference-Cited by-同舟云学术

BCX-1812 (RWJ-270201): Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design

Published:2000-08-31 Issue:19 Volume:43 Page:3482-3486
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Babu Y. Sudhakar¹,Chand Pooran¹,Bantia Shanta¹,Kotian Pravin¹,Dehghani Ali¹,El-Kattan Yahya¹,Lin Tsu-Hsing¹,Hutchison Tracy L.¹,Elliott Arthur J.¹,Parker Cynthia D.¹,Ananth Sandya L.¹,Horn LaShun L.¹,Laver Graeme W.¹,Montgomery John A.¹

Affiliation:

1. BioCryst Pharmaceuticals, Inc., 2190 Parkway Lake Drive, Birmingham, Alabama 35244, and John Curtin School of Medical Research, Australian National University, Canberra 2601, Australia

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm0002679

Reference16 articles.

1. SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICS

2. Clinical and epidemiological importance of influenza a viruses resistant to amantadine and rimantadine

3. Protection against lethal influenza with neuraminidase

Cited by 384 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A “terminal” case of glycan catabolism: structural and enzymatic characterization of the sialidases of Clostridium perfringens;Journal of Biological Chemistry;2024-09

2. A critical analytical aspect on analytical protocols in the pharmaceutical analysis of H1N1 antiviral agent and its active metabolite;Future Journal of Pharmaceutical Sciences;2024-08-28

3. The Development History, Structural Composition, and Functions of Influenza Viruses and the Progress of Influenza Virus Inhibitors in Clinics and Clinical Trials;Mini-Reviews in Medicinal Chemistry;2024-08-07

4. CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase;2024-06-04

5. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”;mBio;2024-05-08